Výsledky vyhledávání

Meet Our Team Our team benefits from decades of know-how and experiences gathered in academic institutions, technology transfer and industrial companies. Using this knowledge, we are developing a pool of highly potent biotech projects originating in academia and finding commercial partners for them. Jiří Moos CEO, Board of Directors Jiří Moos is the Executive Director at i&i Prague. Read More Iva Machová Project Manager Iva Machová is a Project Manager at i&i Prague. Read More Martin Kovalčík Communications Martin Kovalčík is our Communications Manager. Read More Milan Prášil Chairman, Board of directors Milan Prášil is the Chairman of the Board of Directors. Read More Jiří Růžička Project Manager Jiri Ruzicka is a Project manager at i&i Prague. Read More Simona Šandová Office Manager Simona Šandová is the Office Manager of i&i Prague. Read More David Stíbal Board of Directors, Vice Director David Stíbal is the Vice Director at i&i Prague. Read More Roberto Fernandez Project Manager Roberto Fernandez is a Project manager at i&i Prague. Read More Mikuláš Vargic External Lawyer Mikuláš studied law at Masaryk University Brno and International and European Law at the University of Antwerp. Read More Our Mission We scout and support the growth through discovery, pre-seed or seed phase of the most promising projects with innovative potential in Drug Discovery, Diagnostics, MedTech and other Life Science fields. Our Objective Our ambition is to become a leading partner advancing and promoting game-changing biotech inventions coming from the Central Europe region. Our Team Our team benefits from expertise and experience gathered from IOCB and IOCB Tech. We are developing a pool of highly promising biotech projects originating from academia and finding commercial partners for them. Our background We operate as a private company under the wings of the Czech Academy of Sciences and its Institute of Organic Chemistry and Biochemistry (IOCB). From 1994 to 2002, the IOCB was led by Dr. Antonín Holý, whose team invented and developed hugely effective and successful anti-HIV drugs (Truvada, Atripla, Complera, Eviplera). We believe that this is a legacy to build upon and that, with your and our combined expertise, we can make this world a better place and help millions of people.

< Back Roberto Fernandez Project Manager Roberto Fernandez is a Project manager at i&i Prague. He holds a BSc in Chemistry from the University of Costa Rica and a MSc in Biochemistry and Biotechnology from Autonomous University of Barcelona. Prior to joining our company Roberto completed his Ph.D. in Macromolecular Chemistry at Charles University, Czech Republic. His multicultural and multidisciplinary background built his interest for applied science, technology transfer and the positive changes this brings to society. In his last year of Ph.D., he participated in the management internship program started by i&i Prague, which provided hands-on experience working at a start-up in the portfolio of i&i Prague. Parallel to his work in i&i Prague, Roberto works as a project manager in the MedTech start-up LAM-X a.s. Due to his experience, Roberto prefers to focus on projects in the field of medical devices and drug delivery.

< Back Simona Šandová Office Manager During her career, Simona has worked as an Office Manager and a Junior Property Manager. She was responsible for training and conference organization, communication with clients and suppliers as well as administrative assistance for the project and property department. She has considerable experience in administration and office management.

We’ll show you what’s new with us here, offer you interesting media outlets that relate to our work, and you can find our press releases here. Our news We help invention grow! Welcome to the News section of i&i Prague – your go-to source for the latest updates straight from our incubator! This is where we keep you informed about everything happening at i&i Prague. Stay up to date with how we are driving innovation and turning scientific discoveries into real-world solutions. Whether you're a researcher, investor, or entrepreneur, this is the place to discover what’s new at i&i Prague. Highlights Podcast CHEMAGAZÍNtalks podcast presents Jan Berka: "At one point, we held the unofficial record for the longest DNA reading." Read More Interview "I love the feeling you get when you discover something new," says Kamila Burdová, the new incubation manager at i&i Prague. Read More Blog Our "Swiss Journey" Continues: From CometX at the University of Zurich to the Innovation Biotech Day 2025 in Prague Read More Press release i&i Prague and the Nencki Institute launch collaboration to develop an innovative test for early diagnosis of Alzheimer’s disease Read More Press release i&i Prague, Technical University of Liberec, and the Faculty of Medicine of CU in Pilsen will support the Nanoflexion technology Read More Interview Jiří Růžička: The Start-up/Spin-off Gives Scientists the Opportunity to Help Shape the Path of Their Discovery Read More Other news Mar 18 2025 i&i Prague, ÚHKT and Medirekt Partner Join Forces to Bring an Innovative Sample Preparation Technology to Market Read More Feb 25 2025 Czech i&i Prague and the Polish Medical Innovation Institute join forces to support cutting-edge scientific innovation in the region Read More Feb 2 2025 CHEmic podcast with Milan Prasil about how to turn a scientific discovery into a successful start-up/spin-off Read More Jan 20 2025 Neuron 2024 Award for Bridging Science and Business Goes to SophoMer, s.r.o., a Startup from i&i Prague's Portfolio Read More Nov 23 2024 David Stíbal: We believe a startup is one of the best paths nowadays to develop interesting technologies beyond the academic level Read More Nov 7 2024 i&i Prague and other Prague.bio members participate in a business mission with Czech president in Switzerland Read More Oct 30 2024 Jiří Moos: From the lab to the market: What biotech commercialization looks like from the perspective of an incubator Read More Oct 21 2024 PANC-CKI Consortium led by CasInvent Pharma Secures €4M Eurostars Grant for Pancreatic Cancer Research Read More Sep 24 2024 The Prague.bio Conference 2024 welcomed approximately 300 participants from all over the world Read More Mar 11 2024 This fall Prague will be the stage for a showcase of cutting-edge biotechnologies featuring prominent figures such as ... Read More Now 30, 2024 CasInvent Pharma raises € 1.6 million from i&i Prague and Other Investors to Support the Development of CK1 Inhibitors for ... Read More Now 30, 2023 IOCB Tech Group Successfully Represents the Czech Republic at the Prestigious Biotech Conference BIO-Europe 2023 Read More Apr 25, 2023 The Prague.bio international conference will bring together the best of science and business in Prague Read More Feb 7, 2023 New startup in our portfolio: Sophomer's technology will make immunoassays faster, easier and cheaper Read More Feb 6, 2023 Czech liquid biopsy startup Elphogene comes under full control of one of the founders Read More Earlier News

Earlier News We help inventions grow! 2021-2022 Interview with Jaromír Zahrádka: Investments help science to serve people Read more The judges at Transfera Technology Day 2021 awarded the cream of the crop Read more i&i Prague supports the innovative PEP-Therapy in their extension of the Series-A ... Read more Enantis concluded a license agreement for the production of stabilised growth factor FGF2 Read more PerioTrap Pharmaceuticals Raises €3M Seed Round to Develop Selective ... Read more Elphogene received a TA CR grant for “Sample prep system and technology for cancer ..." Read more Our notes from a trip to “The most startup friendly country in the whole world” Read more Spin-off CasInvent Pharma receives the Neuron Award for excellent Technology Transfer Read more Licensing agreement for a novel SARS Cov-2 virus neutralization antibody test was signed Read more i&i Prague supported LAM-X a.s. won the 2020 EIT Health MedTech Bootcamp final ... Read more UCT Prague entered in memorandum with i&i Prague, s.r.o. Read more i&i Prague announces its first exit, DIANA Biotechnologies is bought out by its founders Read more i&i Bio, the newly estabilished investment fund powered by i&i Prague and EIF Read more Green chemistry start-up Sulfotools closes seed round with i&i Prague Read more CasInvent Pharma, an University Spin-Off Focused on Developing Cancer Drugs... Read more Dracen Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With ... Read more 2020-2018 Nanofibers from Technical University of Liberec brings new hope in fight against Covid-19 Read more Enantis – first biotechnology spin-off from Masaryk University in Brno Read more DIANA Biotechnologies – technology that raised EUR 3M in 3 years Read more License for use of iBodies® bought by Immunotech, a member of the Beckman... Read more LAM-X: revolutionary wound-treating nanomaterials Read more Elphogene – liquid biopsy assay for non-invasive monitoring of patients with colorectal cancer Read more Novel partnership for iBodies has been facilitated by i&i Prague and IOCB Tech... Read more i&i Prague became a shareholder in the spin-off XENO Cell Innovations! Read more i&i Prague successfully mediated an out-licensing of antibodies from IMG Read more LAM-X – light-activated nanomaterials for face-masks and respirators Read more Elphogene: non-invasive screening of patients in advanced stages of cancer Read more DRACEN Pharmaceuticals – Novel glutamine antagonist as anticancer therapies Read more iBodies – synthetic antibodies from Institute of Organic Chemistry and Biochemistry Read more Elphogene in World Journal of Gastroenterology! Read more A novel early cancer diagnostics method has been developed at University of Pardubice,... Read more Revolutionary type of catheter raised €2 million from private investors Read more i&i Prague co-invested Dracen Pharmaceuticals, a company developing a novel oncology... Read more Prague startup RIOCATH had recently entered market with its world-unique catheter! Read more Czech anti-covid19 #hackathon won by two i&i Prague accelerated projects Read more LAM-X a.s. is collaborating with TUL to develop active nanofilters against COVID-19 Read more iBodies established cooperation with Ximbio, a TTO within the UK’s largest charity... Read more LAM-X: the spin-off accelerated by i&i Prague in Media Read more DIANA Biotechnologies, a novel startup in the i&i Prague´s academic incubator Read more Startup Riocath is among Hello Tomorrow’s top 500 stratups in the world Read more i&i Prague is joining Hello Tomorrow Ecosystem, a global community boosting deep... Read more

< Back Iva Machová Project Manager Iva Machová is a Project manager at i&i Prague. She is responsible for the analysis of project technology. Before joining our company, Iva worked as a postdoc researcher at the Biomedical Center of the Faculty of Medicine in Pilsen. She holds BSc and MSc degrees from UCT Prague, Czech Republic, and she did her Ph.D. at the Institute of organic chemistry and biochemistry, AS CR. Iva spent several months on a postdoctoral fellowship at Ludwig-Maximilians-Universität München. Due to her scientific experience in biochemistry, she is focused on projects in the field of drug discovery and cell therapy.

< Back Milan Prášil Chairman, Board of directors Milan has a thorough knowledge of a business as well as an academic environment. Functioning for eight years as a chancellor of the oldest and one of the largest universities in Central Europe, Charles University in Prague, Milan’s special assignment was a technological transfer and commercialization of academic research results. Milan is well acquainted with the entrepreneurial environment since he founded and managed a consulting company focused mainly on the assessment and improvement of clinical healthcare efficiency and the assessment and professional development of managers. Before he entered the world of entrepreneurship, Milan had spent a great deal of his early professional career developing expertise in the pharma industry. He initially worked for the Czech branches of research-oriented pharma producers (Novo Nordisk, Bayer) in various positions in sales and marketing. He later gained international senior management experience working at a multinational biotech company (Genzyme Therapeutics), where he was responsible for the process of company expansion to the regions of Central and Eastern Europe. Milan Prasil graduated from the 1st medical faculty of Charles University in Prague (1995) and got his MBA from the Rochester Institute of Technology and the U.S. Business School in Prague (1996).

< Back David Stíbal Board of Directors, Vice Director David Stíbal is the Vice Director at i&i Prague. He holds BSc and MSc degrees from UCT Prague, Czech Republic, and a Ph.D. from the University of Neuchâtel in Switzerland. After his doctorate studies, David worked as a PostDoc at the Massachusetts Institute of Technology. Prior to joining our company, David worked in Lach-Ner s.r.o. as a research scientist, developing modular catalytic systems. His international scientific experience has allowed him to develop a detail-oriented approach to projects from various fields, spanning organic and inorganic chemistry, pharmaceutical sciences, bioinorganic chemistry, and biochemistry. At i&i Prague, David has been focusing on biotechnology evaluations, intellectual property rights, and start-up formation. He will therefore be happy to help assess the scientific background of your project, offer advice during the start-up set-up and early management, and assist in the long-term project development all the way to the successful commercialization.

< Back Mikuláš Vargic External Lawyer Mikuláš studied law at Masaryk University Brno and International and European Law at the University of Antwerp. He is an independent attorney with a specialization in technology transfer. Mikuláš joined our team in 2016 and has almost ten years of experience. He previously worked in a major Czech law firm in Brno and at the South Moravian Innovation Center (JIC). He also works for other clients from both the public sector (universities and research institutions) and the private sector (investors, start-up, and spin-off companies). Mikuláš helps i&i Prague with all legal matters and is involved in negotiating transaction documentation with our partners. His knowledge of business, technical and legal matters will help you to tailor the legal framework for your specific needs.

IOCB Tech Group Successfully Represents the Czech Republic at the Prestigious Biotech Conference BIO-Europe 2023 Over 5,000 participants from more than 50 countries and a total of over 30,000 official meetings – that was the outcome of this year's edition of the international BIO-Europe conference in Munich. The Czech Republic was represented by the companies IOCB Tech, i&i Prague, and i&i Biotech Fund (i&i Bio), which are entities associated with the IOCB Tech Group under the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences. The Czech stand at the event was also supported by representatives of the Consulate General of the Czech Republic in Munich. “IOCB Tech Group regularly participates in BIO-Europe. It is a useful opportunity for us to meet with leading representatives of the biotech, medtech, and life sciences world, as well as investors and scientific research clusters. Thanks also go to the organizers, the EBD Group,” said Martin Fusek, director of IOCB Tech. “BIO-Europe represents a great opportunity for us to meet startups at the forefront of Biotech. Specially, in the CEE region we have found great founders who are shaking the field with their innovative technologies. The event also gives us a chance to reach out to startups which might not have been ready for investment when we originally talked to them, but after some time it is fascinating to see their progress,” adds Roberto Fernandez Alvarez, who represented the incubator i&i Prague with other colleagues. “This year's BIO-Europe was also unique due to the inclusion of a new section of panel discussions on so-called translational funds. These are investors who provide fund financing for the translational phase of research and the technology transfer process. Besides our i&i Bio, four other funds from Germany, Austria, and Belgium were presented, which were also established at significant scientific institutions,” says Jaromír Zahrádka, director of i&i Biotech Fund, adding: “It is evident that such funds have their place in the European venture capital market and often become the initial investor in new projects and biotechnological spin-off companies, which then get the chance to appeal to a broader group of less specialized investors.” The IOCB Tech team conducted more than a hundred meetings and negotiations over three days. “We are particularly grateful for the discussion with the EBD Group regarding the potential hosting of the BIO-Europe conference in Prague, and we are pleased that this vision is also supported by significant clusters such as LISAvienna – Life Science Austria Vienna, BioM Biotech Cluster, Biosaxony association, and many others,” added Martin Opatrný, spokesperson for IOCB Tech. “BIO-Europe represents a great opportunity for us to meet startups at the forefront of Biotech. Specially, in the CEE region we have found great founders who are shaking the field with their innovative technologies. The event also gives us a chance to reach out to startups which might not have been ready for investment when we originally talked to them, but after some time it is fascinating to see their progress,” Roberto Fernandez Alvarez i&i Prague Discussions on cooperation also took place, for example, with the company Symeres, a leading research organization focused on the discovery and development of new drugs. Representatives of the Consulate General in Munich also expressed their support for the IOCB Tech Group, whose visit was a significant recognition of the activities of the IOCB Tech Group. “We are glad to be part of this significant event and present, thanks to IOCB Tech, Czech excellence in the field of life sciences and pharmacy, and thus show the world the innovations and potential of Czech science and technology transfer,” said consul Lukáš Opatrný from the Consulate General of the Czech Republic in Munich. BIO-Europe is an annual meeting of visionaries, innovators, and experts in the field of biotechnology and pharmaceutical research from around the world. Over the past 29 years, BIO-Europe has grown not only in size but especially in becoming the flagship of European biotech. Its international reach is a symbolic gateway to the global life science community. About IOCB Tech The Technology Transfer Office IOCB Tech, s.r.o. is a fully owned subsidiary of the Institute of Organic Chemistry and Biochemistry (IOCB). The main responsibilities of IOCB Tech include the identification of commercially interesting projects at IOCB, analysis of their market potential and patentability, protection of intellectual property, support for the development of the projects in the form of project management, search for commercial partners and negotiation of contractual terms for signing license agreements. IOCB Tech has been involved in the process of negotiating and concluding more than a dozen key license agreements with major pharmaceutical partners such as Gilead Sciences, Merck, Novo Nordisk and SHINE Medical Technologies. In 2017, the company established a subsidiary, i&i Prague, which focuses on funding promising early-stage projects at the Institute and other research and academic institutions. For more information visit www.iocbtech.cz . About i&i Prague The i&i Prague Bio-Innovation Center focuses on the transfer of new technologies into practice. The company was established at the Institute of Organic Chemistry and Biochemistry of the CAS and is mainly dedicated to innovations in the field of drug development, diagnostics and medical devices originating from academic institutions. It supports the creation of spin-off companies and the sale of licenses. So far, the company has participated in the creation of or otherwise supported 15 spin-off companies from five countries, has an equity stake in nine of them and has invested over 70 million crowns. In total, the spin-offs in i&i Prague's portfolio have raised more than CZK 1.8 billion from other investors. In addition to direct financial investments, i&i Prague also assists more than 15 research institutions and universities in the Czech Republic and abroad in the commercialization of innovative technologies. In 2021, i&i Prague started up the i&i Bio investment fund. About i&i Biotech Fund (i&i Bio) i&i Bio is a Luxembourg-based venture capital firm that invests in innovative European Life Sciences companies focused on drug discoveries, medical devices, diagnostics, and digital health. The Fund was created thanks to the cooperation of the biotech incubator i&i Prague and the European Investment Fund (see below). With over €47M under management, i&i Bio plans to invest in about 20 early-stage companies. i&i Bio is led by an experienced team of professionals with backgrounds in private equity, healthcare and venture capital supporting entrepreneurs on their journey to global success. Thanks to close cooperation with the fund’s main sponsor, the biotech academic incubator i&i Prague, i&i Bio is supporting and advancing transformative Central European technology companies. For more information visit www.inibio.eu . About EIF i&i Bio is supported by an investment from the EIF, with the support of: lnnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing; and the Pan-European Guarantee Fund (EGF), implemented by the EIF with the financial support of the Participating Member States. The objective of EGF is to respond to the economic impact of the COVID-19 pandemic by ensuring that companies in the Participating Member States have sufficient short-term liquidity available to weather the crisis and are able to continue their growth and development in the medium to long-term.

i&i Prague announces its first exit, DIANA Biotechnologies is bought out by its founders Prague, 21 February 2022 – BTND a.s. has completed the buyout of DIANA Biotechnologies from the portfolio of biotech incubator i&i Prague. For i&i Prague, the transaction opens up new opportunities to support other scientific projects. i&i Prague acquired a stake in DIANA Biotechnologies at its inception, reflecting the important role of the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB) in the early development of DIANA technology prior to the company’s establishment. However, DIANA Biotechnologies has gradually become a successful biotechnology company that is independently developing a number of other new technologies. It has also made a positive contribution to the fight against the COVID-19 epidemic by developing unique PCR assays, significantly increasing the Czech testing capacity. DIANA Biotechnologies is now facing major investments in further development and it made sense for i&i Prague to make its first exit. BTND a. s., a company backed by DIANA Biotechnologies co-founders Václav Navrátil and Martin Dienstbier, together with the Czech investment group BTCZ, is buying the stake from i&i Prague. „In less than four years DIANA Biotechnologies has moved from a spin-off project to a broad-based and independent company. We are now facing heavy investment in building a state-of-the-art scientific facility and in developing projects in drug development and monoclonal antibody development. Our goal is to build an innovative biopharmaceutical company that will work closely with Czech academia. I am pleased that our success will also help other promising scientific projects,“ said Václav Navrátil, co-founder and director of DIANA Biotechnologies. The transaction is also considered a great success by the incubator i&i Prague, where it is the first purchase of a share of the company from their portfolio. “We were honored to be at the birth of this project. It is the first swallow, which completes several years of efforts of our entire team and which also confirms the sense and correctness of our steps and vision. We will use the funds raised through this transaction to support other interesting startups and spin-off companies from the academic sphere in the Czech Republic and Europe,“ explained Jaromír Zahrádka, founder and director of i&i Prague. About i&i Prague The i&i Prague biotech incubator was founded in 2017 and has become part of a unique ecosystem that has formed around the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB). Since its establishment, this incubator has been dedicated to investing in academia and supporting the transition of scientific discoveries into practice. Currently, i&i Prague has in its portfolio the shares of 10 spin-off companies, promising projects from all over Europe or the USA, in which it has invested a total of approximately EUR 3 million. In addition, it has helped these early stage companies to raise another approximately EUR 75 million from investors not only from Europe but from all over the world. About DIANA Biotechnologies The i&i Prague biotech incubator was founded in 2017 and has become part of a unique ecosystem that has formed around the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB). Since its establishment, this incubator has been dedicated to investing in academia and supporting the transition of scientific discoveries into practice. Currently, i&i Prague has in its portfolio the shares of 10 spin-off companies, promising projects from all over Europe or the USA, in which it has invested a total of approximately EUR 3 million. In addition, it has helped these early stage companies to raise another approximately EUR 75 million from investors not only from Europe but from all over the world.

CasInvent Pharma Raises €1.3 Million from KHAN-I and i&i Biotech Fund to Support the Development of New Casein Kinase 1 Inhibitors for the Treatment of Leukemias and Solid Tumors Prague, Czech Republic, September 13th, 2022. CasInvent Pharma, an early-stage drug discovery company developing small-molecule compounds with anticancer properties, has raised a follow-up investment round of €1.3 million provided by KHAN Technology Transfer Fund I (KHAN-I) and i&i Biotech Fund (i&i Bio). With this funding, CasInvent Pharma will be strengthening its portfolio of casein kinase inhibitors and progressing its lead compound to the development candidate status. The company CasInvent Pharma is developing proprietary, highly selective inhibitors of enzymes belonging to the casein kinase 1 (CK1) family, which play an important role in several disease-related processes, including the migration of leukemia cells into lymphoid organs. The small-molecule inhibitors are designed to target individual isoforms of CK1 and thereby selectively eradicate leukemic cells. The CasInvent inhibitors have shown promising effects on hard-to-treat leukemias, suggesting their potential use in diseases that currently have limited treatment options. Overall, approximately 500,000 new cases and more than 300,000 deaths due to leukemia were recorded worldwide in 2020. CasInvent Pharma will also explore the potential of its CK1 inhibitors for the treatment of other cancers, such as solid tumors. “We are confident that through the support of our investors, we will be able to advance our compounds faster into the clinic and to demonstrate the therapeutic anticancer effects of CK1 inhibition in patients. This step will render CasInvent attractive for larger pharma companies, as it will enable them to expand their portfolio with new compounds useful in single-agent as well as combination therapies,” says Vojtěch Helikar, CEO of CasInvent Pharma. “CK1 inhibition provides a novel mechanism of action in different cancer indications, which needs to be exploited in the clinic. We believe that our compounds have the potential to offer novel alternatives of cancer treatment for patients with a high unmet medical need,” adds Alexander Scheer, CSO of CasInvent Pharma. High quality of the research team and the strong support The company CasInvent Pharma was established in 2020 as a spin-off of Masaryk University (MU) in cooperation with the investment partner i&i Prague. “The investment of €1.3 million further confirms the quality of the scientific project that was created and developed for several years at Masaryk University. The establishment of the spin-off company CasInvent Pharma was thus a logical step to advance, and ultimately commercialize, these efforts. I am very pleased that the Technology Transfer Office of MU was part of such an important achievement,” says Radoslav Trautmann, Head of Technology Transfer Department, Masaryk University. “We are looking forward to our first investment in a Czech start-up and our first co-investment with the recently launched i&i Biotech Fund. From the beginning, we were impressed by the high quality of CasInvent’s research team and the strong support from Masaryk University and the biotech incubator i&i Prague to make this investment possible. With our deep experience in preclinical development of small molecules, we will be able to make valuable contributions to the design and achievement of the key R&D milestones. We look forward to working with Vojtěch, Alexander and the R&D team,” comment Michael Krebs and Peter Nussbaumer, managing partners of KHAN-I. CasInvent Pharma is i&i Bio’s most recent investment announced this year. It marks yet another successful cooperation with the biotech incubator i&i Prague, one of the main investors of i&i Bio. „We are excited to welcome another promising Czech project to our portfolio. The ability of this spin-off to convince renowned international investors confirms its ambition to be successful on a global scale. It is great to be part of this journey. We are also pleased to use our investment to support research that could help treat serious diseases such as leukemia in the future,“ says Ivan Vohlmuth, one of the partners of i&i Bio. Contact Martin Kovalčík, + 420 777 472 863, kovalcik@inibio.eu (for i&i Biotech Fund) Vojtěch Helikar, +420 728 995 850, helikar@casinvent.com (for CasInvent) Radoslav Trautmann, +420 605 824 519, trautmann@casinvent.com (for Masaryk University) Anne-Kathrin Klebl, +49231 97 42 70 29, pr@lead-discovery.de (for KHAN-I) About i&i Bio i&i Bio is a Luxembourg-based venture capital firm that invests in innovative European Life Sciences companies focused on drug discoveries, medical devices, diagnostics, and digital health. The Fund was created thanks to the cooperation of the biotech incubator i&i Prague and the European Investment Fund (see below). With over €45M under management, i&i Bio plans to invest in about 20 early-stage companies. i&i Bio is led by an experienced team of professionals with backgrounds in private equity, healthcare and venture capital supporting entrepreneurs on their journey to global success. Thanks to the close cooperation with the fund’s sponsor, the biotech academic incubator i&i Prague, i&i Bio is supporting and advancing transformative Central European technology companies. For more information visit www.inibio.eu . About European Investment Fund i&i Bio is supported by an investment from the EIF, with the support of: lnnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing; and the Pan-European Guarantee Fund (EGF), implemented by the EIF with the financial support of the Participating Member States. The objective of EGF is to respond to the economic impact of the COVID-19 pandemic by ensuring that companies in the Participating Member States have sufficient short-term liquidity available to weather the crisis and are able to continue their growth and development in the medium to long-term. About KHAN-I KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I) is an early-stage life sciences venture fund with € 70 millions under management. Our mission is to create value through cooperative drug development partnerships with academic innovators in Europe. KHAN-I focuses on first-in-class therapies for attractive markets with a high unmet medical need. The fund is managed by Khanu Management GmbH, an experienced team of professionals with proven track records in early-stage drug development, academic spin-offs as well as pharma licensing and partnering. KHAN-I received an investment from the European Investment Fund (EIF) with support of InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (“EFSI”) under the Investment Plan for Europe. KHAN-I is also supported by Austria Wirtschaftsservice GmbH (AWS with funds provided by the Austrian Federal Ministry for Digital and Economic Affairs and the Austrian Foundation for Research, Technology and Development), Max Planck Foundation and Thyssen’sche Handelsgesellschaft mbH. About Masaryk University Technology Transfer Office Masaryk University Technology Transfer Office is a specialised department of Masaryk University that helps to transfer knowledge and technology into practice. The Office supports the university's cooperation with the commercial sphere, the creation of spin-off companies and the successful commercialisation of university research.